Published in Am J Pathol on October 01, 2006
Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis. Exp Eye Res (2008) 1.63
Glatiramer acetate: evidence for a dual mechanism of action. J Neurol (2008) 1.49
SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci (2007) 1.41
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.03
Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol (2011) 0.90
Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. Am J Pathol (2011) 0.89
T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy (2010) 0.86
Microglial TIR-domain-containing adapter-inducing interferon-β (TRIF) deficiency promotes retinal ganglion cell survival and axon regeneration via nuclear factor-κB. J Neuroinflammation (2012) 0.85
Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. Am J Pathol (2010) 0.84
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol (2008) 0.82
Beneficial effect of chronic Staphylococcus aureus infection in a model of multiple sclerosis is mediated through the secretion of extracellular adherence protein. J Neuroinflammation (2015) 0.81
Neurodegeneration in Autoimmune Optic Neuritis Is Associated with Altered APP Cleavage in Neurons and Up-Regulation of p53. PLoS One (2015) 0.78
Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients. PLoS One (2012) 0.78
Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1. PLoS One (2015) 0.77
Systemic Escherichia coli infection does not influence clinical symptoms and neurodegeneration in experimental autoimmune encephalomyelitis. BMC Neurosci (2015) 0.77
CatWalk gait analysis in a rat model of multiple sclerosis. BMC Neurosci (2016) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol (2000) 4.17
Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol (2001) 4.06
Axonal damage in acute multiple sclerosis lesions. Brain (1997) 3.88
Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron (1988) 3.01
Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol (2000) 2.99
Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol (1998) 2.97
Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med (1999) 2.84
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med (2001) 2.27
Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci (1999) 2.13
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol (1995) 1.71
Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J Neurosci (2003) 1.68
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A (2001) 1.61
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci (2000) 1.44
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology (2000) 1.39
Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci (2001) 1.37
Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ (2004) 1.33
MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest (1998) 1.33
Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-(alpha) rescues axotomized retinal ganglion cells from retrograde cell death in vivo. J Neurosci (2001) 1.29
Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler (2005) 1.21
Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol (2005) 1.19
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2003) 1.14
Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology (2002) 1.13
Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci (2003) 1.11
Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol (1995) 1.10
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology (1999) 1.10
Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol (2003) 1.10
Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain (2004) 1.04
Differences in survival-promoting effects and intracellular signaling properties of BDNF and IGF-1 in cultured cerebral cortical neurons. J Neurochem (2001) 0.99
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol (2005) 0.91
Magnetic resonance spectroscopy: imaging axonal damage in MS. J Neuroimmunol (1999) 0.90
The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol (2003) 0.90
Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res (2003) 0.90
Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother (2001) 0.89
Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology (2000) 0.88
Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. Brain Pathol (2004) 0.87
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology (2001) 0.82
Environment-dependent down-modulation of CD45 cell surface expression on polymorphonuclear cells. J Clin Lab Anal (2004) 0.79
Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J Neurol Sci (2005) 0.79
Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology (2001) 0.78
Interventions for the prevention of brain atrophy in multiple sclerosis : current status. CNS Drugs (2003) 0.78
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci (2004) 2.36
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain (2008) 2.18
β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann Neurol (2013) 2.10
An optical coherence tomography study on degeneration of retinal nerve fiber layer in rats with autoimmune optic neuritis. Invest Ophthalmol Vis Sci (2012) 2.02
ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain (2007) 1.87
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A (2010) 1.70
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol (2013) 1.70
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem (2007) 1.59
Lack of the Kir4.1 channel subunit abolishes K+ buffering properties of astrocytes in the ventral respiratory group: impact on extracellular K+ regulation. J Neurophysiol (2005) 1.57
Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol (2006) 1.55
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol (2008) 1.45
Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2004) 1.44
Disruption of maternal parenting circuitry by addictive process: rewiring of reward and stress systems. Front Psychiatry (2011) 1.42
TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol (2006) 1.41
Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain (2005) 1.37
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol (2013) 1.34
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci Lett (2004) 1.33
Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke (2006) 1.29
Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis (2002) 1.28
HDAC1 regulates fear extinction in mice. J Neurosci (2012) 1.27
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull (2007) 1.26
Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke (2008) 1.20
Transfection of "naked" siRNA results in endosomal uptake and metabolic impairment in cultured neurons. Biochem Biophys Res Commun (2004) 1.18
Dual role of the Saccharomyces cerevisiae TEA/ATTS family transcription factor Tec1p in regulation of gene expression and cellular development. Eukaryot Cell (2002) 1.17
Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler (2013) 1.16
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem (2006) 1.16
Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol (2011) 1.13
MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. Acta Neuropathol (2013) 1.13
Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci (2003) 1.11
alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis (2007) 1.11
Survival and Axonal Elongation of Adult Rat Retinal Ganglion Cells. Eur J Neurosci (1989) 1.08
Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther (2011) 1.06
Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci (2002) 1.06
TAT-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. J Cereb Blood Flow Metab (2009) 1.05
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis (2007) 1.05
Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain (2004) 1.04
Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol (2002) 1.04
Progressive loss of a glial potassium channel (KCNJ10) in the spinal cord of the SOD1 (G93A) transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem (2006) 1.04
Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke (2003) 1.04
Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res (2006) 1.04
Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuropathol (2006) 1.03
Interleukin-1 beta protects neurons via the interleukin-1 (IL-1) receptor-mediated Akt pathway and by IL-1 receptor-independent decrease of transmembrane currents in vivo. Mol Cell Neurosci (2003) 1.03
Preclinical retinal neurodegeneration in a model of multiple sclerosis. J Neurosci (2012) 1.03
Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: therapeutic potential against ischemic stroke after intrastriatal and systemic transplantation. Stem Cells (2012) 1.02
Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain (2012) 1.02
MRI of optic neuritis in a rat model. Neuroimage (2008) 1.02
ROCKing Regeneration: Rho Kinase Inhibition as Molecular Target for Neurorestoration. Front Mol Neurosci (2011) 1.02
Varicella zoster virus cerebellitis in a 66-year-old patient without herpes zoster. Lancet (2006) 1.01
Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol (2011) 1.01
Growth and guidance cues for regenerating axons: where have they gone? J Neurobiol (2004) 1.01
Intracellular delivery of Neuroglobin using HIV-1 TAT protein transduction domain fails to protect against oxygen and glucose deprivation. Neurosci Lett (2007) 1.00
Early and sustained activation of autophagy in degenerating axons after spinal cord injury. Brain Pathol (2014) 1.00
The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis. Brain (2012) 0.99
Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve (2007) 0.98
Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep (2007) 0.97
Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease. Atherosclerosis (2011) 0.97
Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo. J Neurochem (2011) 0.96
Axotomy-induced early down-regulation of POU-IV class transcription factors Brn-3a and Brn-3b in retinal ganglion cells. J Mol Neurosci (2005) 0.96
Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA (2006) 0.96
Correlation of optical coherence tomography with clinical and histopathological findings in experimental autoimmune uveoretinitis. Exp Eye Res (2011) 0.96
Expression time course and spatial distribution of activated caspase-3 after experimental status epilepticus: contribution of delayed neuronal cell death to seizure-induced neuronal injury. Neurobiol Dis (2005) 0.96
Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. Ann Neurol (2009) 0.95
Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism. J Med Chem (2006) 0.95
Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application. Neurodegener Dis (2004) 0.95
Interaction of BAG1 and Hsp70 mediates neuroprotectivity and increases chaperone activity. Mol Cell Biol (2005) 0.95
Teaching NeuroImages: Ma2 encephalitis presenting as acute panhypopituitarism in a young man. Neurology (2013) 0.95
Synthesis of cell-penetrating peptides and their application in neurobiology. Methods Mol Biol (2007) 0.95
Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol Cell Neurosci (2009) 0.94
Glial cell line-derived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury. Am J Physiol Renal Physiol (2007) 0.94
Long-term in vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary neurons. Biochem Biophys Res Commun (2005) 0.93